Gilead Sciences (GILD) Operating Expenses (2009 - 2026)
Gilead Sciences' (GILD) quarterly Operating Expenses came in at $4.4 billion in Q1 2026, down 1.26% YoY from $4.4 billion in Q1 2025, and down 26.38% on a QoQ basis from $5.9 billion in Q4 2025.
Gilead Sciences (GILD) Operating Expenses (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Operating Expenses data on file, last reported at $4.4 billion in Q1 2026.
- Quarterly Operating Expenses fell 1.26% year-over-year to $4.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 billion (down 5.6% YoY) and the FY2025 annual result came in at $19.4 billion, down 28.31% from the prior year.
- Operating Expenses retreated to $4.4 billion in Q1 2026, from $5.9 billion in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $11.0 billion in Q1 2024 to a low of $4.2 billion in Q3 2022.
- A 5-year average of $5.3 billion and a median of $4.6 billion in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses soared 136.88% — and 2025, when it tumbled 59.76%.
- Tracing GILD's Operating Expenses over 5 years: stood at $5.1 billion in 2022, then climbed by 7.42% to $5.5 billion in 2023, then declined by 7.0% to $5.1 billion in 2024, then increased by 16.1% to $5.9 billion in 2025, then slipped by 26.38% to $4.4 billion in 2026.
- The last three Operating Expenses figures came in at $4.4 billion (Q1 2026), $5.9 billion (Q4 2025), and $4.4 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.20 Bn |
| Mar 31, 2026 | 4.37 Bn |
| Dec 31, 2025 | 5.94 Bn |
| Sep 30, 2025 | 4.44 Bn |
| Jun 30, 2025 | 4.61 Bn |
| Mar 31, 2025 | 4.43 Bn |
| Dec 31, 2024 | 5.12 Bn |
| Sep 30, 2024 | 6.66 Bn |
| Jun 30, 2024 | 4.31 Bn |
| Mar 31, 2024 | 11.01 Bn |
| Dec 31, 2023 | 5.50 Bn |
| Sep 30, 2023 | 4.43 Bn |
| Jun 30, 2023 | 4.93 Bn |
| Mar 31, 2023 | 4.65 Bn |
| Dec 31, 2022 | 5.12 Bn |
| Sep 30, 2022 | 4.21 Bn |
| Jun 30, 2022 | 4.23 Bn |
| Mar 31, 2022 | 6.39 Bn |
| Dec 31, 2021 | 6.30 Bn |
| Sep 30, 2021 | 3.58 Bn |